Skip to main content
SpringerLink
Log in

Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol

  • Published:
Cellular and Molecular Neurobiology Aims and scope Submit manuscript

Abstract

1. Human cytochrome P450 (CYP) isoenzymes expressed in a human cell line were used to elucidate their involvement in the metabolism of haloperidol (HAL).

2. It was found that CYP3A4 catalyzes the metabolism of HAL to HAL 1,2,3,6-tetrahydropyridine (HTP). HTP is further metabolized to HAL pyridinium (HP+) by both CYP3A4 and CYP2D6.

3. CYP3A4 and CYP2D6 are also responsible for the N-dealkylation of HAL. The N-dealkylation of reduced HAL (RH) was observed, which is catalyzed by CYP3A4. In addition, CYP3A4 also catalyzes the oxidation of RH back to HAL.

4. These results are discussed in terms of the metabolic interactions of HAL with other drugs and how this knowledge may be used to reduce the movement disorders induced by HAL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Daniel, D. G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., and Linnoila, M. (1994). Coadministration of fluvoxamine increases serum concentrations of haloperidol. J. Clin. Psychopharmacol. 14:340–343.

    Google Scholar 

  • Fang, J., and Gorrod, J. W. (1991). Dehydration is the first step in the biotransformation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 59:117–123.

    Google Scholar 

  • Fang, J., and Gorrod, J. W. (1993). An HPLC system for the analysis of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614:267–273.

    Google Scholar 

  • Fang, J., Zuo, D. M., and Yu, P. H. (1995). A comparison of a quaternary pyridinium metabolite of haloperidol (HP+) with the neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology 121:373–378.

    Google Scholar 

  • Fang, J., Baker, G. B., and Coutts, R. T. (1996). Determination of 4-chlorophehyl-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection. J. Chromatogr. Biomed. Appl. 682:283–288.

    Google Scholar 

  • Forsman, A., and Larsson, M. (1978). Metabolism of haloperidol. Curr. Ther. Res. 24:567–568.

    Google Scholar 

  • Goff, D. C., Midha, K. K., Brotman, A. W., Waites, M., and Baldessarini, R. J. (1991). Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am. J. Psychiatry 148:790–792.

    Google Scholar 

  • Gorrod, J. W., and Fang, J. (1993). On the metabolism of haloperidol. Xenobiotica 23:459–508.

    Google Scholar 

  • LLerena, A., Alm, C., Dahl, M-.L., Ekqvist, B., and Bertilsson, L. (1992). Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14:92–97.

    Google Scholar 

  • Rollema, H., Skolnik, M., d'Engelbronner, J., Igarashi, K., Usuki, E., and Castagnoli, N., Jr. (1994). MPP+-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:380–387.

    Google Scholar 

  • Soudijn, W., Van Wijngaarden, I., and Allewijn, F. (1967). Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur. J. Pharmacol. 1:47–57.

    Google Scholar 

  • Subramanyam, B., Rollema, H., Woolf, T., and Castagnoli, N., Jr. (1990). Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166:238–244.

    Google Scholar 

  • Tate, J. L. (1989). Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am. J. Psychiatry 146:399–400.

    Google Scholar 

  • Tyndale, R. F., Kalow, W., and Inaba, T. (1991). Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br. J. Clin. Pharmacol. 31:655–660.

    Google Scholar 

  • Young, D., Midha, K. K., Fossler, M. J., Hawes, E. M., Hubbard, J. W., McKay, G., and Korchinski, E. D. (1993). Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6. Eur. J. Clin. Pharmacol. 44:433–438.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurochemical Research Unit, Department of Psychiatry and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2B7, Canada

    Jian Fang, Glen B. Baker, Peter H. Silverstone & Ronald T. Coutts

Authors
  1. Jian Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glen B. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter H. Silverstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald T. Coutts
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, J., Baker, G.B., Silverstone, P.H. et al. Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol. Cell Mol Neurobiol 17, 227–233 (1997). https://doi.org/10.1023/A:1026317929335

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026317929335

Search

Navigation